The dry AMD pipeline is packed. Join New Retina Radio as we break it down with Peter Kaiser, MD, whose podium presentation at AAO 2025 offered a survey of developmental projects in dry AMD. What should we look forward to? And Michel Michaelides, MD, shares details from the DRAGON study, which examined the safety and efficacy of tinlarebant (Belite Bio) for the treatment of Stargardt disease. Could a once-daily oral tablet lead to positive outcomes for patients? Listen to the episode to learn more.